About
CDI Bioscience has developed an innovative technology for increased yield of bioproducts, manufactured in cellular systems. Genetic engineering technology is used to control the metabolism of cells, thus shifting the cell from replicative to production mode (RP Shift®). In particular, this technology has been designed for use in mammalian cells, unlocking their potential to produce proteins, peptides and enzymes. The current design of the technology can be readily translated to bacterial and yeast cellular systems for the production of commercial grade bioproducts.
Position in the VCSift Database
- • 4,609 investors in VCSift focus on the biotech sector.
- • 126 investors are based in Madison, Wisconsin, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- biotech
- Location
- Madison, US
Contact Information
Find more investors like CDI
Search Investors